Clinical trial
Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group
NCT01524848 is registered in ClinicalTrials.gov with Scandinavian Sarcoma Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group
- Lead sponsor
- Scandinavian Sarcoma Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 29, 2012
- Completion date
- November 30, 2016
- Enrollment
- 72 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.